ITGAM and pancreatic neuroendocrine tumor: Sorafenib-resistant pancreatic neuroendocrine tumors exhibit enrichment of PI3Kr CD11b+ immune cells (MDSCs), along with increased infiltration of pro-tumor Gr1+ monocytes and neutrophils [43].